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BACKGROUND: Elevated B-type natriuretic peptide (BNP) is reflective of impaired 
cardiac function and is associated with worse prognosis among patients with coronary 
artery disease (CAD). We sought to assess the association between baseline BNP, 
adverse outcomes, and the relative efficacy of percutaneous coronary intervention 
(PCI) versus coronary artery bypass grafting (CABG) in patients with left main CAD.
METHODS: The EXCEL trial (Evaluation of XIENCE Versus Coronary Artery Bypass 
Surgery for Effectiveness of Left Main Revascularization) randomized patients with 
left main CAD and low or intermediate SYNTAX scores (Synergy Between PCI With 
TAXUS and Cardiac Surgery) to PCI with everolimus-eluting stents versus CABG. 
The primary end point was the composite of all-cause death, myocardial infarction, 
or stroke. We used multivariable Cox proportional hazards regression to assess 
the associations between normal versus elevated BNP (≥100 pg/mL), randomized 
treatment, and the 3-year risk of adverse events.
RESULTS: BNP at baseline was elevated in 410 of 1037 (39.5%) patients enrolled 
in EXCEL. Patients with elevated BNP levels were older and more frequently had 
additional cardiovascular risk factors and lower left ventricular ejection fraction 
than those with normal BNP, but had similar SYNTAX scores. Patients with elevated 
BNP had significantly higher 3-year rates of the primary end point (18.6% versus 
11.7%; adjusted hazard ratio [HR], 1.62; 95% confidence interval [CI], 1.16–2.28; 
P=0.005) and higher mortality (11.5% versus 3.9%; adjusted HR, 2.49; 95% CI, 
1.48–4.19; P=0.0006), both from cardiovascular and noncardiovascular causes. In 
contrast, there were no significant differences in the risks of myocardial infarction, 
stroke, ischemia-driven revascularization, stent thrombosis, graft occlusion, or 
major bleeding. A significant interaction (Pinteraction=0.03) was present between 
elevated versus normal BNP and treatment with PCI versus CABG for the adjusted 
risk of the primary composite end point at 3 years among patients with elevated 
BNP (adjusted HR for PCI versus CABG, 1.54; 95% CI, 0.96–2.47) versus normal 
BNP (adjusted HR, 0.74; 95% CI, 0.46–1.20). This interaction was stronger when 
log(BNP) was modeled as a continuous variable (Pinteraction=0.002).
CONCLUSIONS: In the EXCEL trial, elevated baseline BNP levels in patients with 
left main CAD undergoing revascularization were independently associated with 
long-term mortality but not nonfatal adverse ischemic or bleeding events. The 
relative long-term outcomes after PCI versus CABG for revascularization of left 
main CAD may be conditioned by the baseline BNP level.
CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov. Unique 
identifier: NCT01205776.
© 2018 American Heart Association, Inc.
Björn Redfors, MD, PhD*
Shmuel Chen, MD, PhD*
Aaron Crowley, MA
Ori Ben-Yehuda, MD
Bernard J. Gersh, MB, 
ChB, DPhil
Nicholas J. Lembo, MD
W. Morris Brown III, MD
Adrian P. Banning, MD
David P. Taggart, MD, PhD
Patrick W. Serruys, MD, 
PhD
Arie Pieter Kappetein, 
MD, PhD
Joseph F. Sabik III, MD
Gregg W. Stone, MD
ORIGINAL RESEARCH ARTICLE
B-Type Natriuretic Peptide Assessment in Patients 
Undergoing Revascularization for Left Main 
Coronary Artery Disease
Analysis From the EXCEL Trial
https://www.ahajournals.org/journal/circ
Circulation
April32018
D
ow
nloaded from
 http://ahajournals.org by on January 14, 2019
Redfors et al BNP and Outcomes After Left Main Revascularization
July 31, 2018 Circulation. 2018;138:469–478. DOI: 10.1161/CIRCULATIONAHA.118.033631470
OR
IG
IN
AL
 R
ES
EA
RC
H 
AR
TI
CL
E
B-type natriuretic peptide (BNP) is secreted in re-sponse to increased atrial and ventricular pressure and volume loads,1,2 but may also be elevated in 
response to myocardial hypoxia.3,4 Elevated BNP has 
been independently associated with a worse prognosis 
in patients with ischemic heart disease,5–9 and with mor-
tality after noncardiac10,11 as well as cardiac surgery.12 
However, the prognostic implications of BNP after treat-
ment of left main (LM) coronary artery disease (CAD) 
have not been studied, and whether having elevated 
versus normal baseline BNP is associated with the rela-
tive outcomes after LMCAD revascularization by per-
cutaneous coronary intervention (PCI) compared with 
coronary artery bypass grafting (CABG) is unknown.13
The EXCEL trial (Evaluation of XIENCE Versus Coro-
nary Artery Bypass Surgery for Effectiveness of Left Main 
Revascularization) demonstrated that in patients with 
LMCAD and low or intermediate SYNTAX scores (Syner-
gy Between PCI With TAXUS and Cardiac Surgery), PCI 
with everolimus-eluting stents was noninferior to CABG 
with respect to the rate of the composite end point of 
death, stroke, or myocardial infarction (MI) at 3 years.14 
We sought to assess the association between baseline 
BNP and adverse outcomes after LMCAD treatment, 
and whether the relative efficacy of PCI versus CABG 
differs for patients with elevated versus normal BNP.
METHODS
Study Design and Study Population
The study design, protocol, and primary results of the EXCEL 
trial have been previously described in detail.14,15 In brief, EXCEL 
was a prospective, international, unblinded, multicenter, ran-
domized trial that compared coronary stenting versus CABG in 
patients with LMCAD. Key inclusion criteria were visually esti-
mated diameter stenosis of the LM coronary artery ≥70%, or 
>50% to <70% if determined by means of noninvasive or inva-
sive testing to be hemodynamically significant; a site-assessed 
SYNTAX score ≤3216; and a consensus among the members of 
the heart team regarding eligibility for revascularization with 
either PCI or CABG. Eligible patients were randomized 1:1 to 
undergo either PCI with cobalt–chromium fluoropolymer-based 
everolimus-eluting XIENCE stents (Abbott Vascular, Santa Clara, 
CA) or CABG. The trial conformed to the Declaration of Helsinki 
and was approved by the investigational review board or eth-
ics committee at each participating center. All patients signed 
informed consent before randomization. The data, analytic 
methods, and study materials are proprietary to the sponsor 
and will not be made available to other researchers for purposes 
of reproducing the results or replicating the procedure.
Definitions
The primary end point of the EXCEL trial was the rate of a 
composite of death from any cause, stroke, or MI at 3 years. 
The definitions of MI as well as other end points have been 
previously reported.14 An independent clinical events com-
mittee reviewed and adjudicated all adverse events. A base-
line BNP level was recommended to be drawn in all patients. 
BNP ≥100 pg/mL was defined as elevated based on previous 
studies demonstrating that a cutoff of 100 pg/mL predicted 
mortality and cardiovascular adverse events among patients 
with heart failure17 and stable CAD.18 The same definition 
of elevated BNP was used in the TOPCAT trial (Treatment of 
Preserved Cardiac Function Heart Failure with an Aldosterone 
Antagonist).19,20
Statistical Analysis
Comparisons of baseline and procedural characteristics, med-
ical history, and clinical events were conducted by χ2 test or 
Fisher exact test for categorical variables, Student t test or 
Pearson correlation for continuous variables, and log-rank test 
for time-to-event variables. Adjusted comparisons were con-
ducted using multivariable Cox proportional hazards regres-
sion. The association between BNP and adverse outcomes 
was adjusted for the following covariables: randomized treat-
ment, age, sex, body mass index, diabetes mellitus, smoking, 
previous MI, clinical presentation (acute coronary syndrome 
versus stable CAD), chronic kidney disease, peripheral vascu-
lar disease, chronic obstructive pulmonary disease, anemia, 
and baseline SYNTAX score. We tested for statistical interac-
tions between BNP and randomized treatment by including 
Clinical Perspective
What Is New?
• In patients with left main coronary artery disease 
undergoing revascularization in the EXCEL trial, 
elevated baseline B-type natriuretic peptide (BNP) 
was associated with a higher risk of 3-year all-
cause, cardiovascular, and noncardiovascular mor-
tality, but not of nonlethal ischemic events.
• The association between BNP and mortality per-
sisted after adjustment for risk factors, including 
history of congestive heart failure, left ventricu-
lar ejection fraction, and SYNTAX score (Synergy 
Between PCI With TAXUS and Cardiac Surgery).
• Event-free survival after coronary artery bypass 
grafting was relatively independent of baseline BNP, 
whereas the 3-year composite rate of death, myo-
cardial infarction, or stroke after percutaneous cor-
onary intervention rose with increasing BNP level.
What Are the Clinical Implications?
• For patients with left main coronary artery disease 
undergoing revascularization, measuring baseline 
BNP levels can add prognostic information beyond 
traditional cardiovascular risk factors, including left 
ventricular ejection fraction and the SYNTAX score.
• The relative long-term outcomes after percutane-
ous coronary intervention versus coronary artery 
bypass grafting for revascularization of left main 
coronary artery disease may be conditioned by the 
baseline BNP level, with higher BNP levels favoring 
coronary artery bypass grafting and lower BNP lev-
els favoring percutaneous coronary intervention.
D
ow
nloaded from
 http://ahajournals.org by on January 14, 2019
Redfors et al BNP and Outcomes After Left Main Revascularization
Circulation. 2018;138:469–478. DOI: 10.1161/CIRCULATIONAHA.118.033631 July 31, 2018 471
ORIGINAL RESEARCH 
ARTICLE
interaction terms between BNP and treatment in the adjusted 
models. We examined outcomes in patients with elevated 
versus normal baseline BNP levels, as well as in analyses in 
which BNP was modeled as a continuous variable (using the 
logarithmic scale). Additional multivariable models were fit 
that also adjusted for left ventricular ejection fraction (LVEF) 
and a history of congestive heart failure (CHF), in addition 
to the covariable set listed above (fully adjusted models). To 
further account for these 2 factors, 2 sensitivity models were 
fit: one stratified multivariable model using the same covari-
able set listed above with different strata for patients with 
normal LVEF (defined as LVEF >50%) and the absence of CHF 
versus patients with either reduced LVEF or CHF, and another 
multivariable model that was restricted to patients with nor-
mal LVEF and absence of CHF. A final sensitivity analysis using 
multivariable shared frailty Cox proportional hazards mod-
els accounted for the possible clustering of patients within 
treating hospitals. The relationship between BNP and the risk 
of adverse outcomes was further explored by entering log-
transformed BNP as a nonlinear term (penalized spline with 
2 degrees of freedom) in Cox proportional hazards regression 
models separately for PCI and CABG patients.21,22 Firth’s bias 
reduction method was applied to all statistical models per-
taining to individual end points to mitigate the risk of model 
overfitting.23,24 All tests were 2-sided, and P<0.05 was con-
sidered statistically significant. Statistical analyses were per-
formed with SAS version 9.4 (SAS Institute, Cary, NC).
RESULTS
Study Population and Patient 
Characteristics
A total of 1905 patients with LMCAD from 126 cen-
ters in 17 countries were randomized in the EXCEL 
trial; baseline BNP data were available in 1037 patients 
(54.4%), constituting the present study cohort. Base-
line characteristics for patients with and without data 
on BNP are presented in Table I in the online-only Data 
Supplement. The distribution of BNP among the cohort 
is presented in Figure I in the online-only Data Supple-
ment, demonstrating a nonnormal right-skewed pat-
tern with a median (interquartile range) of 70.0 (23.7–
198.0) pg/mL, ranging from 0.2 to 6178.0 pg/mL. BNP 
was elevated (≥100 pg/mL) in 410 of 1037 (39.5%) pa-
tients. Baseline characteristics of patients with elevated 
versus normal BNP are presented in Table 1. Elevated 
BNP was associated with older age, a higher preva-
lence of cardiovascular risk factors, and lower LVEF. 
Patients with elevated BNP were more likely than pa-
tients with normal BNP to present with MI, but angio-
graphic characteristics were not significantly different 
among patients with elevated and normal BNP, includ-
ing the SYNTAX score (Table 2). BNP considered as a 
continuous variable (log[BNP]) was not correlated with 
diameter stenosis (correlation coefficient, 0.03; 95% 
confidence interval [CI], −0.03 to 0.09; P=0.37), lesion 
length (correlation coefficient, −0.02; 95% CI, −0.08 
to 0.05; P=0.62), or baseline SYNTAX score (correlation 
coefficient, 0.00; 95% CI, −0.06 to 0.06; P=0.73). Dur-
ing the course of the study, patients with elevated BNP 
were more likely than patients with normal BNP to be 
treated with angiotensin-converting enzyme inhibitors 
or angiotensin receptor blockers, aldosterone antago-
nists, nitrates, oral anticoagulants, and antiarrhythmic 
drugs but not antiplatelet drugs, beta blockers, or 
statins (Table II in the online-only Data Supplement).
Table 1. Baseline Characteristics in Patients With Normal and Elevated 
Baseline BNP
 
Normal BNP 
<100 pg/mL
N=627
Elevated BNP 
≥100 pg/mL
N=410 P Value
Geographic region
  Europe 439/627 (70.0) 309/410 (75.4) 0.06
  North America 133/627 (21.2) 92/410 (22.4) 0.64
  Asia 12/627 (1.9) 3/410 (0.7) 0.002
  South America 31/627 (4.9) 6/410 (1.5) 0.003
Age, y 64.7±9.4 67.2±9.4 <0.0001
Female 137/627 (21.9) 114/410 (27.8) 0.03
Body mass index, kg/m2 28.3±4.7 28.3±4.6 0.99
Hypertension 445/627 (71.0) 323/410 (78.8) 0.005
Hyperlipidemia 445/626 (71.1) 297/410 (72.4) 0.64
Diabetes mellitus 172/627 (27.4) 116/410 (28.3) 0.76
  Insulin-treated 34/627 (5.4) 33/410 (8.0) 0.09
Hemoglobin A1c, % 6.2±1.3 6.1±1.0 0.81
Current cigarette smoker 130/625 (20.8) 93/408 (22.8) 0.45
Previous PCI 89/627 (14.2) 58/408 (14.2) 0.99
Chronic obstructive 
pulmonary disease
32/626 (5.1) 39/409 (9.5) 0.006
Congestive heart failure 31/625 (5.0) 37/408 (9.1) 0.009
Peripheral vascular disease 43/624 (6.9) 49/408 (12.0) 0.005
Chronic kidney disease* 84/618 (13.6) 89/402 (22.1) 0.0004
Dialysis 1/627 (0.2) 1/410 (0.2) 0.99
Left ventricular ejection 
fraction, %
58.4±8.3 55.5±10.3 <0.0001
  ≤40% 19/574 (3.3) 37/401 (9.2) <0.0001
Presenting clinical syndrome
  Recent MI† 66/626 (10.5) 76/409 (18.6) 0.0002
  ST-segment–elevation MI 5/623 (0.8) 9/407 (2.2) 0.06
  Non–ST-segment–
elevation MI
58/623 (9.3) 64/407 (15.7) 0.002
  Unstable angina 169/626 (27.0) 104/409 (25.4) 0.58
  Stable angina 355/626 (56.7) 206/409 (50.4) 0.05
  Other‡ 36/627 (5.74) 23/410 (5.61) 0.93
Values are n/N (%) or mean±SD. BNP indicates B-type natriuretic peptide; MI, 
myocardial infarction; and PCI, percutaneous coronary intervention.
*Creatinine clearance <60 mL/min as calculated by the Cockcroft-Gault 
formula. 
†Occurred within 7 days.
‡Silent ischemia, dyspnea, cardiomyopathy, or other. 
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Clinical Outcomes
The relative 3-year risk of adverse events after CABG 
versus PCI was consistent in patients with versus 
without data on BNP (Table III in the online-only Data 
Supplement). The unadjusted and adjusted 3-year 
risk of the primary end point of death, stroke, or MI 
was significantly higher for patients with elevated 
versus normal BNP (Table 3, Figure 1). This was driv-
en primarily by a higher risk of death (11.5% versus 
3.9%; adjusted hazard ratio [HR], 2.49 [1.48–4.19; 
P=0.0006]), whereas the 3-year unadjusted and 
adjusted risks of MI, stroke, repeat revasculariza-
tion, stent thrombosis or graft occlusion, and major 
bleeding were not significantly different between 
the two groups (Table 3, Figure II in the online-only 
Data Supplement). The risks of both cardiovascular 
and noncardiovascular death were greater in patients 
with elevated compared with normal BNP levels. The 
association between BNP and adverse outcomes was 
similar when BNP was modeled as a continuous vari-
able, with steadily increasing mortality with greater 
BNP levels (adjusted HR, 1.31 per each 10-fold in-
crease in BNP; 95% CI, 1.13–1.53; P=0.0004; Fig-
ure III in the online-only Data Supplement, Table IV 
in the online-only Data Supplement). When LVEF and 
a history of CHF were added to the covariable set, 
elevated BNP (whether considered as a continuous 
or categorical variable) remained significantly associ-
ated with a higher risk of the primary end point, all-
cause death, and noncardiovascular death, but not 
cardiovascular death (Table 3, Table IV in the online-
only Data Supplement).
With BNP considered as a categorical variable, a 
significant interaction was present between elevated 
versus normal BNP and treatment with PCI versus 
CABG for the adjusted risk of the primary compos-
ite end point at 3 years (adjusted HR for PCI versus 
CABG, 1.54; 95% CI, 0.96–2.47 among patients 
with elevated BNP versus adjusted HR, 0.74; 95% 
CI, 0.46–1.20 among patients with normal BNP; Pin-
teraction=0.03; Table 4). This interaction remained sig-
nificant when LVEF and history of CHF were added 
to the covariable set (Pinteraction=0.04; Table  5). Simi-
larly, there was a statistically significant interaction 
between baseline BNP and treatment for the risk of 
the primary end point when BNP was modeled as a 
continuous variable (Pinteraction=0.002; Figure  2, Table 
IV in the online-only Data Supplement, Figure IV in 
the online-only Data Supplement), which persisted 
after addition of LVEF and CHF to the covariable set 
(Pinteraction=0.002; Table  6). The observed interaction 
between baseline BNP and treatment with PCI versus 
CABG with regard to the 3-year risk of the primary 
end point also persisted when the statistical model 
was stratified by whether patients had normal LVEF 
without CHF, as well as when the analysis population 
was restricted to patients with normal LVEF without 
CHF (Table 6). Last, the interaction between BNP and 
treatment modality persisted after accounting for 
possible clustering of patients within specific hospi-
tals, irrespective of whether BNP was modeled as a 
categorical or continuous variable (Table 6). The re-
sults pertaining to nonfatal end points were consis-
tent in analyses in which Fine-Gray subdistribution 
hazards regression was used to adjust for death as a 
competing risk.
Table 2. Angiographic and Procedural Characteristics in Patients With 
Normal and Elevated Baseline BNP
 
Normal BNP 
<100 pg/mL
N=627
Elevated BNP 
≥100 pg/mL
N=410 P Value
Number of non-LM diseased vessels
  0 109/620 (17.6) 65/403 (16.1) 0.55
  1 208/620 (33.5) 131/403 (32.5) 0.73
  2 200/620 (32.3) 127/403 (31.5) 0.80
  3 103/620 (16.6) 80/403 (19.9) 0.19
LM diameter stenosis, % 64.8±12.4 65.2±12.0 0.71
LM lesion location
  Ostial lesion 230/604 (38.1) 142/394 (36.0) 0.51
  Midshaft 261/604 (43.2) 160/394 (40.6) 0.42
  Distal lesion 475/604 (78.6) 309/394 (78.4) 0.94
  Bifurcation lesion 268/475 (56.4) 181/309 (58.6) 0.55
SYNTAX score (baseline)* 26.4±9.3 27.1±8.7 0.16
  0 to 22 223/607 (36.7) 117/391 (29.9) 0.03
  23 to 32 241/607 (39.7) 178/391 (45.5) 0.07
  >32 143/607 (23.6) 96/391 (24.6) 0.72
Residual SYNTAX score 6.1±6.6 6.8±6.3 0.14
PCI procedural characteristics
  Staged procedure(s) 
planned
21/329 (6.4) 19/218 (8.7) 0.30
  Distal LM bifurcation PCI 187/306 (61.1) 116/198 (58.6) 0.57
  Provisional 1-stent strategy 130/187 (69.5) 75/116 (64.7) 0.38
  Planned 2-stent strategy 57/187 (30.5) 41/116 (35.3) 0.38
  Number of stents in LM 1.5±0.7 1.5±0.8 0.97
  Number of treated non-
LM vessels
0.7±0.8 0.7±0.8 0.55
CABG procedural characteristics
  Off-pump CABG 106/307 (34.5) 90/202 (44.6) 0.02
  Number of conduits 2.5±0.7 2.4±0.7 0.04
  Number of arterial 
conduits
1.5±0.6 1.3±0.5 0.0006
  Procedure duration, min 249.3±66.9 226.7±74.0 <0.0001
  Cross clamp duration, min 57.1±29.1 53.4±22.8 0.50
Values are n/N (%) or mean±SD. BNP indicates B-type natriuretic peptide; 
CABG, coronary artery bypass grafting; LM, left main coronary artery; PCI, 
percutaneous coronary intervention; and SYNTAX, Synergy Between PCI With 
TAXUS and Cardiac Surgery.
*Core laboratory assessed SYNTAX score. 
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DISCUSSION
The major findings from the present analyses from the 
EXCEL trial are that among patients with LMCAD and 
low or intermediate SYNTAX scores undergoing revas-
cularization, (1) elevated baseline BNP levels were asso-
ciated with a higher 3-year risk of the primary compos-
ite end point of death, MI or stroke, driven by greater 
mortality from both cardiovascular and noncardiovas-
cular causes, but not of nonfatal adverse ischemic or 
bleeding events; and (2) a significant interaction was 
present between baseline BNP level and revasculariza-
tion by PCI versus CABG for the 3-year primary com-
posite end point such that event-free survival was rela-
tively higher in patients with lower BNP levels after PCI, 
whereas the relative risk of the primary composite end 
point was relatively lower in patients with higher base-
line BNP levels after CABG.
Patients in EXCEL who had elevated BNP levels at 
baseline had a considerably higher adjusted risk of dy-
ing after treatment for LMCAD than those with normal 
BNP. This is consistent with previous reports from other 
patient cohorts with ischemic heart disease.5–9 The ob-
served association between BNP and excess mortality 
may in part be related to impaired cardiac function 
among patients with elevated BNP, as in the present 
study patients with an elevated BNP had a lower LVEF 
and higher prevalence of congestive heart failure than 
those with lower BNP levels. However, in EXCEL, as 
well as in several other studies, the relationship be-
tween BNP and LVEF was modest6,8; most patients had 
a LVEF within the normal range and were free from 
overt heart failure (even those in whom BNP was ele-
vated), and the association between elevated BNP and 
higher mortality persisted after adjustment for LVEF 
and a history of CHF. Furthermore, previous studies 
have reported modest relationships between BNP and 
other indices of cardiac function, and the association 
between BNP and excess mortality has persisted after 
adjustment for both systolic and diastolic dysfunction.6 
Thus, BNP appears to be a useful prognostic biomarker 
for mortality in patients with CAD with and without 
heart failure.
Recent studies have demonstrated that BNP is se-
creted from hypoxic myocardium, even in the absence 
of left ventricular dysfunction.3,4 BNP may thus be a 
marker of myocardial ischemia,25 with reduced event-
free survival.26–28 A role has also been suggested for 
Table 3. Unadjusted and Adjusted 3-Year Risk of Adverse Clinical Outcomes Associated With Elevated Versus Normal B-Type  
Natriuretic Peptide
3-Year Outcomes
Unadjusted 
Hazard Ratio (95% 
Confidence Interval) Punadjusted
Adjusted Hazard 
Ratio*
(95% Confidence 
Interval) Padjusted*
Fully Adjusted 
Hazard Ratio†
(95% Confidence 
Interval) Padjusted†
Primary end point‡ 1.63 (1.18–2.24) 0.003 1.62 (1.16–2.28) 0.005 1.61 (1.13–2.28) 0.008
  All-cause death 3.09 (1.89–5.07) <0.0001 2.49 (1.48–4.19) 0.0006 2.19 (1.29–3.73) 0.004
   Cardiovascular death 3.05 (1.47–6.33) 0.003 2.36 (1.11–5.01) 0.03 2.06 (0.95–4.44) 0.07
   Noncardiovascular death 3.12 (1.60–6.10) 0.0009 2.61 (1.27–5.35) 0.009 2.33 (1.12–4.86) 0.02
  Myocardial infarction 1.10 (0.70–1.71) 0.69 1.21 (0.76–1.92) 0.43 1.27 (0.79–2.03) 0.33
  Stroke 1.34 (0.60–3.00) 0.47 1.16 (0.50–2.72) 0.73 1.11 (0.45–2.75) 0.82
Ischemia-driven revascularization 0.95 (0.62–1.47) 0.82 0.94 (0.60–1.46) 0.77 1.02 (0.65–1.62) 0.92
Stent thrombosis/graft occlusion 0.60 (0.27–1.35) 0.21 0.54 (0.24–1.24) 0.15 0.56 (0.24–1.33) 0.19
BARC 3–5 bleeding 1.45 (0.88–2.39) 0.14 1.32 (0.79–2.21) 0.29 1.35 (0.79–2.32) 0.27
BARC indicates Bleeding Academic Research Consortium.
*Adjusted for the following covariables: randomized treatment, age, sex, body mass index, diabetes mellitus, smoking, previous myocardial infarction, clinical 
presentation (acute coronary syndrome vs. stable coronary artery disease), chronic kidney disease, peripheral vascular disease, chronic obstructive pulmonary disease, 
anemia, and baseline SYNTAX score.
†Adjusted for the covariable set used in * plus congestive heart failure and left ventricular ejection fraction. 
‡The composite of all-cause death, myocardial infarction, or stroke.
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627 578 571 564 553 545 501
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11.7%
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Figure 1. Kaplan–Meier failure rates for the occurrence of the 3-year 
primary end point in patients with elevated versus normal B-type 
natriuretic peptide. 
The primary end point was the composite of all-cause death, myocardial 
infarction, and stroke at 3-year follow-up. BNP indicates B-type natriuretic 
peptide; CI, confidence interval; and HR, hazard ratio.
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natriuretic peptides in the regulation of metabolic 
pathways related to lipolysis and glucose homeosta-
sis, which are both important in the pathophysiology 
of ischemic heart disease and atherosclerosis.29 Con-
sistent with these reports, an elevated baseline natri-
uretic peptide level has been associated with a higher 
risk of late adverse ischemic events (not just mortality) 
in some studies of patients with CAD treated conser-
vatively.5,6 In the present large-scale study, however, 
no significant associations were present between 
baseline BNP levels and nonfatal ischemic events, 
including MI, stroke, stent thrombosis, symptomatic 
graft occlusion, and repeat revascularization. This 
discordance from previous studies may be explained 
by the performance of effective revascularization in 
EXCEL, thereby reducing the ischemic burden. Un-
fortunately, serial BNP levels postprocedure were not 
assessed, which precludes determining whether BNP 
levels declined after LMCAD revascularization (and 
with high compliance with guideline-directed medi-
Table 4. Crude 3-Year Kaplan–Meier Event Rates and Adjusted Hazard Ratios of Adverse Clinical Outcomes for Patients Treated With PCI Versus 
CABG According to B-Type Natriuretic Peptide
Normal BNP (<100 pg/mL) Elevated BNP (≥100 pg/mL)
PinteractionPCI CABG
Adj. Hazard Ratio 
(95% Confidence 
Interval) PCI CABG
Adj. Hazard Ratio 
(95% Confidence 
Interval)
Primary end point* 10.3% (32) 13.1% (41) 0.74 (0.46–1.20) 21.1% (42) 16.1% (33) 1.54 (0.96–2.47) 0.03
  Death 4.5% (14) 3.2% (10) 1.19 (0.52–2.70) 12.6% (25) 10.3% (21) 1.38 (0.75–2.55) 0.77
  Myocardial infarction 6.5% (20) 8.6% (27) 0.81 (0.44–1.48) 8.1% (16) 8.4% (17) 1.08 (0.55–2.15) 0.53
  Stroke 1.0% (3) 3.2% (11) 0.34 (0.10–1.20) 4.2% (10) 1.6% (5) 3.60 (0.10–1.20) 0.02
Ischemia-driven revascularization 11.2% (34) 6.8% (21) 1.63 (0.94–2.85) 10.5% (20) 6.7% (13) 1.75 (0.86–3.54) 0.88
  Target vessel 9.2% (28) 6.8% (21) 1.33 (0.75–2.38) 9.4% (18) 6.3% (12) 1.69 (0.81–3.55) 0.62
  Target lesion 7.2% (22) 6.5% (20) 1.15 (0.62–2.14) 8.4% (16) 5.7% (11) 1.58 (0.73–3.45) 0.53
Stent thrombosis or graft occlusion 1.0% (3) 5.8% (18) 0.17 (0.05–0.57) 0% (0) 4.1% (8) — —
Adjusted for the following covariables: randomized treatment, age, sex, body mass index, diabetes mellitus, smoking, previous myocardial infarction, clinical 
presentation (acute coronary syndrome vs. stable coronary artery disease), chronic kidney disease, peripheral vascular disease, chronic obstructive pulmonary disease, 
anemia, and baseline SYNTAX score. Adj. indicates adjusted; CABG, coronary artery bypass grafting; and PCI, percutaneous coronary intervention.
*The composite of all-cause death, myocardial infarction, or stroke.
Table 5. Interaction Sensitivity Analyses: Hazard Ratios for Elevated BNP Versus Normal BNP for Patients 
Undergoing CABG and PCI
Primary End Point*
Hazard Ratio (95% Confidence Interval) PCI Versus CABG
Elevated BNP Normal BNP Pinteraction
Fully adjusted model 1.54 (0.96–2.48) 0.76 (0.47–1.25) 0.04
Sensitivity Model I 1.54 (0.96–2.47) 0.74 (0.46–1.19) 0.03
Sensitivity Model II† 1.52 (0.84–2.76) 0.72 (0.41–1.24) 0.07
Sensitivity Model III 1.52 (0.94–2.45) 0.75 (0.46–1.23) 0.04
Fully adjusted model: Multivariable Cox proportional hazards regression adjusted for the covariate set: age, sex, 
body mass index, diabetes mellitus, smoking, previous myocardial infarction (MI), clinical presentation (acute coronary 
syndrome vs. stable coronary artery disease [CAD]), chronic kidney disease, peripheral vascular disease, chronic obstructive 
pulmonary disease, anemia, and baseline SYNTAX score, congestive heart failure (CHF), left ventricular ejection fraction 
(LVEF). Sensitivity Model I: Stratified multivariable Cox proportional hazards regression adjusted for the following covariate 
set: age, sex, body mass index, diabetes mellitus, smoking, previous MI, clinical presentation (acute coronary syndrome 
vs. stable CAD), chronic kidney disease, peripheral vascular disease, chronic obstructive pulmonary disease, anemia, and 
baseline SYNTAX score, and stratified according to the absence of CHF with normal LVEF (defined as LVEF>50%) vs. either 
the presence of CHF or a reduced LVEF.
Sensitivity Model II: Multivariable Cox proportional hazards regression adjusted for the covariate set: age, sex, body mass 
index, diabetes mellitus, smoking, previous MI, clinical presentation (acute coronary syndrome vs. stable CAD), chronic kidney 
disease, peripheral vascular disease, chronic obstructive pulmonary disease, anemia, and baseline SYNTAX score, and with the 
study population restricted to patients without CHF and with a normal ejection fraction (N=697 [67% of the study cohort]).
Sensitivity Model III: Multivariable Shared Frailty Cox proportional hazards regression adjusted for the covariate set: 
age, sex, body mass index, diabetes mellitus, smoking, previous MI, clinical presentation (acute coronary syndrome vs. 
stable CAD), chronic kidney disease, peripheral vascular disease, chronic obstructive pulmonary disease, anemia, baseline 
SYNTAX score, CHF, LVEF and geographic region (North America vs. Europe vs. Other), and with site of enrollment included 
in the model as a random effect. BNP indicates B-type natriuretic peptide; CABG, coronary artery bypass grafting; and PCI, 
percutaneous coronary intervention.
*Composite of all-cause death, MI, or stroke. 
†Because of a smaller number of events, the Firth correction was used.
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cal therapy as practiced in EXCEL).14 In this regard, 
persistently elevated BNP levels may portend a worse 
prognosis than elevated BNP levels that subsequently 
decline or normalize.30,31
An interaction was present between baseline BNP 
level and revascularization type for the primary 3-year 
composite end point of death, MI, or stroke. Specifi-
cally, as seen in Figure 2, after adjustment for differ-
ences in important covariables, event-free survival af-
ter CABG was relatively independent of baseline BNP 
level, whereas the 3-year composite rate of death, MI, 
or stroke after PCI rose steadily with increasing base-
line BNP level. As a result, 3-year event-free survival 
was relatively higher after PCI in patients with lower 
BNP levels, whereas the risk of the primary composite 
end point was relatively lower after CABG in patients 
with higher baseline BNP levels. These data are con-
sistent with the association noted between reduced 
cardiac function and worse outcomes after PCI com-
pared with CABG in the SYNTAX trial.32 The mecha-
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Figure 2. Adjusted association between B-type natriuretic peptide (BNP) and the 3-year risk of adverse clinical outcomes according  
to revascularization assignment. 
Multivariable Cox proportional hazards regression. Shown is the adjusted hazard ratio associated with percutaneous coronary intervention (PCI) vs. coronary artery 
bypass grafting (CABG) for patients according to baseline BNP levels, modeled as a log-linear continuous variable, as regards (A) the risk of the 3-year primary 
composite end point, and (B) all-cause death. The P value refers to the interaction between treatment assignment and the linear term for log(BNP). CI indicates 
confidence interval.
Table 6. Interaction Sensitivity Analyses: Hazard Ratios per 10-Fold Increase in BNP for Patients Undergoing 
CABG and PCI
Primary End Point*
Hazard Ratio (95% Confidence Interval) Per 10-Fold Increase in BNP
PCI CABG Pinteraction
Fully adjusted model 1.32 (1.14–1.53) 0.95 (0.82–1.10) 0.002
Sensitivity Model I 1.33 (1.16–1.54) 0.97 (0.85–1.11) 0.001
Sensitivity Model II† 1.26 (1.05–1.52) 0.97 (0.81–1.16) 0.04
Sensitivity Model III 1.33 (1.14–1.54) 0.96 (0.83–1.11) 0.002
Fully adjusted model: Multivariable Cox proportional hazards regression adjusted for the covariate set: age, sex, 
body mass index, diabetes mellitus, smoking, previous myocardial infarction (MI), clinical presentation (acute coronary 
syndrome vs. stable coronary artery disease [CAD]), chronic kidney disease, peripheral vascular disease, chronic obstructive 
pulmonary disease, anemia, and baseline SYNTAX score, congestive heart failure (CHF), left ventricular ejection fraction 
(LVEF). Sensitivity Model I: Stratified multivariable Cox proportional hazards regression adjusted for the following covariate 
set: age, sex, body mass index, diabetes mellitus, smoking, previous MI, clinical presentation (acute coronary syndrome 
vs. stable CAD), chronic kidney disease, peripheral vascular disease, chronic obstructive pulmonary disease, anemia, and 
baseline SYNTAX score, and stratified according to the absence of CHF with normal LVEF (defined as LVEF>50%) vs. either 
the presence of CHF or a reduced LVEF.
Sensitivity Model II: Multivariable Cox proportional hazards regression adjusted for the covariate set: age, sex, body 
mass index, diabetes mellitus, smoking, previous MI, clinical presentation (acute coronary syndrome vs. stable CAD), 
chronic kidney disease, peripheral vascular disease, chronic obstructive pulmonary disease, anemia, and baseline SYNTAX 
score, and with the study population restricted to patients without CHF and with a normal ejection fraction (N=697 [67% 
of the study cohort]).
Sensitivity Model III: Multivariable Shared Frailty Cox proportional hazards regression adjusted for the covariate set: 
age, sex, body mass index, diabetes mellitus, smoking, previous MI, clinical presentation (acute coronary syndrome vs. 
stable CAD), chronic kidney disease, peripheral vascular disease, chronic obstructive pulmonary disease, anemia, baseline 
SYNTAX score, CHF, LVEF and geographic region (North America vs. Europe vs. Other), and with site of enrollment 
included in the model as a random effect. BNP indicates B-type natriuretic peptide; CABG, coronary artery bypass 
grafting; and PCI, percutaneous coronary intervention.
*Composite of all-cause death, MI, or stroke.
†Because of a smaller number of events, the Firth correction was used.
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nisms underlying this observation are uncertain. In the 
SYNTAX trial, complete revascularization was achieved 
more frequently after CABG compared with PCI (an 
analysis that is pending from EXCEL),16 which may be 
particularly important in patients with elevated BNP 
levels attributable to impaired cardiac function33 and 
extensive ischemia.34 However, the interaction be-
tween BNP and revascularization method with regard 
to the risk of the primary composite end point per-
sisted after adjustment for LVEF, CHF, and the SYNTAX 
score. Whether elevated BNP levels reflect aspects of 
ischemia or cardiac function that are not routinely as-
sessed (eg, diastolic dysfunction) and that are more 
effectively treated with CABG than PCI remains to be 
established.
Study Strengths and Limitations
As the largest randomized trial to date of patients with 
LMCAD undergoing revascularization, EXCEL provides 
useful insights into the association between baseline 
BNP and the risk of adverse outcomes after contem-
porary LMCAD treatment. However, several limitations 
should be considered. First, the present analysis was 
post hoc, and the findings should thus be considered 
exploratory. Second, assessment of BNP levels was not 
mandated, and modest differences in baseline charac-
teristics were present between patients in whom BNP 
measures were and were not assessed. Local labora-
tories were used for BNP measurement, which may 
also have added some imprecision. Although the case 
report form asked specifically for BNP and sites were 
trained to collect this biomarker, we cannot rule out 
that some sites assessed N-terminal pro-BNP; howev-
er, the results were consistent in models that adjusted 
for site as a random effect. Third, with a sample size 
of 1037 patients, our study may not have sufficient 
statistical power to detect subtle associations between 
BNP and adverse clinical outcomes. However, to our 
knowledge, the present study represents the largest 
prospective cohort of patients with baseline BNP data 
who underwent LM revascularization. Fourth, despite 
multivariable analysis, unmeasured confounders may 
not have been identified. Fifth, although the interac-
tion between baseline BNP level and revascularization 
type on the 3-year occurrence of the primary outcome 
measure was strong, subgroup testing was not adjust-
ed for multiplicity, and this observation should be con-
sidered hypothesis generating. Additional studies are 
needed to clarify whether patients with LMCAD and 
high BNP levels should preferentially undergo CABG, 
and conversely whether low BNP levels connote a par-
ticular benefit from LMCAD revascularization by PCI. 
Sixth, follow-up is complete only through 3 years, and 
longer-term surveillance is necessary to determine 
whether further differences between PCI and CABG 
emerge over time, in all patients and as a function 
of baseline BNP level. Finally, our findings only apply 
to the patients enrolled in the present study, namely 
those with LMCAD and low or intermediate SYNTAX 
scores with clinical and anatomic equipoise for per-
cutaneous or surgical revascularization. Relatively few 
patients had markedly reduced left ventricular func-
tion, and although ≈25% of randomized subjects had 
high SYNTAX scores by angiographic core laboratory 
analysis, further studies are required to determine 
whether BNP may play an even greater prognostic role 
in such patients.
CONCLUSIONS
In the EXCEL trial, patients with LMCAD and elevated 
BNP levels undergoing revascularization had higher 
3-year rates of the primary composite outcome measure 
of death, MI, or stroke, driven by greater cardiovascular 
and noncardiovascular mortality, compared with those 
with a normal BNP. The relative long-term outcomes after 
PCI versus CABG for revascularization of LMCAD may be 
conditioned by the baseline BNP level, with higher BNP 
levels favoring CABG and lower BNP levels favoring PCI.
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